Cellogen Therapeutics, a Delhi-based biotechnology startup focused on cellular engineering, has successfully raised ₹20 crore (approximately $2 million) in fresh funding from Kotak Alternate Asset Managers through its Kotak Life Sciences Fund I. Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, the deep-tech healthcare company is building advanced Chimeric Antigen Receptor T-cell (CAR-T) therapies and gene-editing solutions. Backed previously by NATCO Pharma, the firm intends to deploy this new capital injection to aggressively advance its clinical programs, expand its broader gene therapy pipeline, and fortify its GMP-compliant manufacturing infrastructure to meet stringent regulatory standards for upcoming human trials.
The core investment thesis behind this ₹20 crore round centers entirely on solving a severe pricing bottleneck in modern oncology. Globally, advanced CAR-T cell therapies—which involve extracting a patient’s T-cells, genetically engineering them to hunt cancer cells, and re-infusing them—can cost upwards of ₹4 crore ($500,000 to $700,000) per patient. This renders the treatment fundamentally inaccessible to the vast majority of the Indian population. Cellogen Therapeutics is attacking this exact vulnerability by building a fully indigenous, IP-led platform. By leveraging AI-driven drug development and focusing on next-generation bispecific CAR-T therapies that target two disease markers instead of one to prevent relapse, the company aims to slash the end-consumer cost by up to 90%. Structuring a highly localized supply chain and manufacturing process allows them to target a price point of $60,000 to $70,000 without compromising clinical efficacy.
Zooming out, this funding event signals a maturation of the Indian biotech ecosystem, moving beyond generic pharmaceutical manufacturing into the complex realm of novel biologic IP creation. Historically, India has carried a massive burden of blood cancers and genetic disorders like beta-thalassemia and sickle cell disease, yet it has remained dependent on prohibitively expensive Western innovations for advanced cures. The institutional backing from Kotak Alts validates the commercial viability of "Make in India" deep-tech healthcare. If Cellogen successfully navigates its Phase I clinical trials and brings its targeted therapies to market at a fraction of the global cost, it will not only capture a significant share of the domestic oncology market but also position India as a global export hub for affordable, high-quality gene therapy solutions across emerging economies.
For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.